Concord Biotech Ltd. (CONCORDBIO) Receives a Hold from Jefferies
Jefferies analyst Alok Dalal maintained a Hold rating on Concord Biotech Ltd. (CONCORDBIO – Research Report) today and set a price target of INR1,700.00. The company's shares closed yesterday at INR1,748.50.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Dalal covers the Healthcare sector, focusing on stocks such as Ajanta Pharma Limited, Cipla Ltd, and Concord Biotech Ltd.. According to TipRanks, Dalal has an average return of 2.2% and a 55.17% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Concord Biotech Ltd..
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
41 minutes ago
- Business Insider
Scentre Group (STGPF) was upgraded to a Hold Rating at Macquarie
In a report released today, from Macquarie upgraded Scentre Group (STGPF – Research Report) to a Hold, with a price target of A$3.24. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Scentre Group has an analyst consensus of Strong Buy, with a price target consensus of $2.51. The company has a one-year high of $3.09 and a one-year low of $1.59. Currently, Scentre Group has an average volume of 9,213.
Business Insider
41 minutes ago
- Business Insider
Centuria Capital Group (CNI) was upgraded to a Buy Rating at Macquarie
Centuria Capital Group (CNI – Research Report) received a Buy rating and a A$1.78 price target from Macquarie analyst today. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Centuria Capital Group with a A$1.82 average price target. Based on Centuria Capital Group's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$229.42 million and a GAAP net loss of A$518 thousand. In comparison, last year the company earned a revenue of A$136.06 million and had a net profit of A$45.21 million
Business Insider
an hour ago
- Business Insider
Rubrik, Inc. Class A (RBRK) Receives a Buy from Barclays
In a report released on May 30, Saket Kalia from Barclays maintained a Buy rating on Rubrik, Inc. Class A (RBRK – Research Report), with a price target of $105.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Kalia covers the Technology sector, focusing on stocks such as Adobe, Autodesk, and PTC. According to TipRanks, Kalia has an average return of 16.7% and a 64.69% success rate on recommended stocks. In addition to Barclays, Rubrik, Inc. Class A also received a Buy from Guggenheim's John Difucci in a report issued on May 27. However, on May 15, Mizuho Securities downgraded Rubrik, Inc. Class A (NYSE: RBRK) to a Hold. Based on Rubrik, Inc. Class A's latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $258.1 million and a GAAP net loss of $114.89 million. In comparison, last year the company earned a revenue of $175.01 million and had a GAAP net loss of $97.5 million Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBRK in relation to earlier this year. Most recently, in April 2025, Ravi Mhatre, a Director at RBRK sold 13,213.00 shares for a total of $832,154.74.
